U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07050732) titled 'Immunogenicity of RSVPreF3 Vaccine in Immunocompromised Persons' on June 25.
Brief Summary: This clinical trial is being done to learn more about how well a vaccine (Arexvy(R)) for respiratory syncytial virus, also known as RSV, works in people with weakened immune systems. The main questions it aims to answer are:
* Does 1 or 2 doses of Arexvy work better in people with weakened immune systems?
* What medical problems do participants have after receiving Arexvy?
Participants with weakened immune systems will:
* Receive 3 study vaccines over the course of 1 year
* Keep a diary of symptoms for 7 days after each vaccine
* Have 3 ...